127 related articles for article (PubMed ID: 2367445)
21. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
[TBL] [Abstract][Full Text] [Related]
22. [Results of 6-month and 9-month treatments with rifampin, isoniazid and ethambutol in cases of newly detected tuberculosis].
Szymanski A; Gaik A
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1981; 30(3):181-3. PubMed ID: 6273991
[No Abstract] [Full Text] [Related]
23. [Treatment of 100 pulmonary tubercular patients whose bacilli are resistant to streptomycin, isoniazid and ethionamid, with a combination of rifampicin and ethambutol. Comparison between 2 dosages of rifampicin (weekly treatment for 4 months, biweekly for 8 months after)].
Hétrick G; Muñoz I; Ras R
Rev Tuberc Pneumol (Paris); 1970; 34(5):715-6. PubMed ID: 5496795
[No Abstract] [Full Text] [Related]
24. [Comparative study (in a controlled therapeutic trial) of 3 intermittent regimens, after an initial period of daily administration, in the repeated treatment of pulmonary tuberculosis (results)].
Fraga H; Gomes O; Paz de Almeida A; Gerhardt G; Santiago AC
Bull Int Union Tuberc; 1973 Jun; 48(0):125-38. PubMed ID: 4602467
[No Abstract] [Full Text] [Related]
25. [Results of treatment of newly detected pulmonary tuberculosis with rifampin combined with isoniazid and ethambutol].
Szymański A; Walecki J; Czaplińska-Jóźwiak E; Kuczborska Z; Gaik A; Bilczak Z; Swiatnicka I; Swica T; Zdawski T
Pneumonol Pol; 1980 Nov; 48(11):669-74. PubMed ID: 7255207
[No Abstract] [Full Text] [Related]
26. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
27. Tuberculosis therapy and enzyme induction in man.
Larousse C; Le Normand Y; Kergueris MF; Veyrac MJ; Chailleux E; Ordronneau J; Moigneteau C
Int J Clin Pharmacol Ther Toxicol; 1980 Apr; 18(4):163-8. PubMed ID: 7380590
[TBL] [Abstract][Full Text] [Related]
28. [Effectiveness of the rapid intravenous administration of rifampicin and isoniazid and of the intramuscular administration of streptomycin in disseminated destructive pulmonary tuberculosis in dogs].
Bondarev IM; Ivanov VL; Novoselova VP; Kovaleva LA; Shtegel'man LA
Antibiotiki; 1984 Jun; 29(6):430-4. PubMed ID: 6476805
[TBL] [Abstract][Full Text] [Related]
29. Population screening for isoniazid acetylator phenotype.
Seifart HI; Parkin DP; Botha FJ; Donald PR; Van Der Walt BJ
Pharmacoepidemiol Drug Saf; 2001; 10(2):127-34. PubMed ID: 11499851
[TBL] [Abstract][Full Text] [Related]
30. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
Singh S; Mohan B
Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
[TBL] [Abstract][Full Text] [Related]
31. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
Ahn HC; Lee YC
Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing the effects of the initial phase of tuberculosis chemotherapy.
Tousek J; Zítková L; Trnka L; Staflová S; Papezová E; Drápela J
Czech Med; 1980; 3(2):114-22. PubMed ID: 7418568
[TBL] [Abstract][Full Text] [Related]
33. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
34. [Remote results of short-term treatment of pulmonary tuberculosis with a combination of isoniazid, rifampin and ethambutol].
Sosnowski W; Krawczyk Z; Górnicka-Wilczyńska M; Pilarska-Machowicz A; Pruszyńska S; Pawlik J; Wardowa A; Woźniak B; Tomaszkiewicz L
Pneumonol Pol; 1980 Nov; 48(11):663-8. PubMed ID: 7255206
[No Abstract] [Full Text] [Related]
35. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R;
Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacokinetic bases for the drug-free prevention of drug-induced hepatitis in pulmonary tuberculosis patients].
Koriakin VA; Sokolova GB; Ziia AV; Zeliger LR; Ivleva AIa
Ter Arkh; 1987; 59(7):75-7. PubMed ID: 3672366
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of oral and intravenous rifampicin during chronic administration.
Loos U; Musch E; Jensen JC; Mikus G; Schwabe HK; Eichelbaum M
Klin Wochenschr; 1985 Dec; 63(23):1205-11. PubMed ID: 4087830
[TBL] [Abstract][Full Text] [Related]
38. [Diphasic treatment of pulmonary tuberculosis in children using rifamycin, ethambutol and isoniazid].
Bethlem N; Alves JP; Dias L; de Andrade EM; Tavares W; Franca JL; Tavares WC
Hospital (Rio J); 1970 Jul; 78(1):35-48. PubMed ID: 5312452
[No Abstract] [Full Text] [Related]
39. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
Roy V; Tekur U; Chopra K
Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
[TBL] [Abstract][Full Text] [Related]
40. [Rifampicin in experimental tuberculosis].
Kradolfer F
Schweiz Med Wochenschr; 1968 Sep; 98(36):1363. PubMed ID: 5680480
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
